CING (Cingulate) Moat Score: 2/10 (As of Jun. 26, 2026)


CING Cingulate Inc CING
35 GF Score
Price $4.94
! 1 Warning Sign
View Full Analysis

What is Cingulate Moat Score?

Cingulate CING +4.20% 35 Moat Score is 2 as of Jun. 26, 2026. GuruFocus rates CING with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 1,404 Biotechnology companies, Cingulate ranks better than 58.12% on this metric.

Cingulate has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Cingulate has No Moat: Cingulate Inc lacks significant market share, brand strength, and intellectual property. It operates in a competitive pharmaceutical industry with limited regulatory barriers or customer switching costs.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Cingulate might have No Moat - Very weak/transient advantages.

Cingulate  (NAS:CING) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Cingulate Moat Score Related Terms

CING vs TIL, XLO, GOSS: Moat Score Comparison

For the Biotechnology subindustry, Cingulate's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cingulate Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cingulate's Moat Score distribution charts can be found below:

* The bar in red indicates where Cingulate's Moat Score falls into.


CING
35GF Score
Cingulate Inc CING
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Cingulate (CING) has a Moat Score of 2 as of Jun. 26, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Cingulate ranks #588 out of 1404 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Cingulate's Moat Score too high?
Cingulate's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Cingulate's value of 2 is 0% at this industry median. Based on the distribution chart, Cingulate ranks #588 out of 1404 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cingulate has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cingulate's Moat Score compare to TIL and XLO?
According to the Biotechnology industry distribution chart, Cingulate ranks #588 out of 1404 companies for Moat Score. This puts Cingulate in the upper half of its industry. The industry median Moat Score is 2.00. Cingulate's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cingulate's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cingulate's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cingulate stock overvalued right now?
Cingulate (CING) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Cingulate's overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Cingulate (CING), the current Moat Score is 2 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cingulate Business Description

Address 1901 West 47th Place, Kansas, KS, USA, 66205
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
35GF Score

Get the complete analysis for CING

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.94
Price